GLYATL2

Across TCGA pan-cancer cohorts, GLYATL2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GLYATL2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GLYATL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GLYATL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC and LSCC are the cancer types where GLYATL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.803	0.494	.023	8	view →
LSCC	DFS	Quartile	All	0.945	1.000	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GLYATL2–HNSC (DFS)

Open the HNSC breakdown →